Terns pharmaceuticals selected for oral presentation at european hematology association congress for preclinical data on novel allosteric bcr-abl inhibitor tern-701

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of bcr-abl including difficult-to-treat resistance mutations
ABL Ratings Summary
ABL Quant Ranking